Advertisement
LH vs SYK
Which Stock Would AI Choose? Labcorp Holdings (LH) vs. Stryker Corporation (SYK) Stock Comparison
Key Takeaways
- Labcorp Holdings (LH) trades at a lower trailing P/E ratio (price-to-earnings) of 25.18 compared to Stryker Corporation's (SYK) 39.21, offering better relative valuation.
- Both stocks show positive year-to-date gains, with SYK at 6.14% slightly ahead of LH's 5.27%, amid healthcare sector resilience.
- SYK reports stronger quarterly revenue growth of 11.4% versus LH's 5.6%, driven by orthopaedics demand.
- LH benefits from recent FDA-approved diagnostics launches, boosting oncology offerings.
- Market caps differ significantly: SYK at $126B dwarfs LH's $21.7B, reflecting scale in medical devices.
- Both await Q1 earnings with growth expectations, but LH shows slight recent monthly upside momentum.
Introduction
Labcorp Holdings (LH) and Stryker Corporation (SYK) represent key players in the healthcare sector, with LH focused on diagnostics and laboratory services, and SYK leading in medical devices and orthopaedics. This stock comparison analyzes their recent market performance, financial metrics, and growth drivers amid evolving healthcare demands. Traders seeking sector exposure and investors evaluating relative value in diagnostics versus devices will find insights into momentum, valuations, and upcoming catalysts like quarterly earnings. Both exhibit stability with betas near 1.0, but contrasts in scale and pricing offer trade-offs for diversified portfolios.
LH Overview and Recent Performance
Labcorp Holdings Inc. (LH) is a leading provider of laboratory diagnostic services, operating in Diagnostics Laboratories and Biopharma segments. It delivers tests for routine health checks, specialty diagnostics in oncology, genetics, and infectious diseases, serving physicians, hospitals, and biopharma clients. In recent market activity, LH shares have traded around $263, below its 50-day moving average (MA) of $272 but with modest monthly gains of about 1%. Sentiment has been influenced by anticipation for Q1 earnings projecting $3.5 billion in revenue and $4.09 EPS (earnings per share), alongside a new FDA-approved companion diagnostic for ovarian cancer treatment eligibility. Analyst upgrades to Buy reflect optimism on growth in precision medicine, though shares remain range-bound near the 52-week midpoint.
SYK Overview and Recent Performance
Stryker Corporation (SYK) specializes in medical technologies, spanning MedSurg/Neurotechnology and Orthopaedics segments. Its portfolio includes implants for joint replacements, surgical equipment, and robotic systems like Mako for hip, knee, and shoulder procedures, sold globally to hospitals. Recent weeks have seen SYK shares hover near $329, down about 1.5% monthly and further below its 50-day MA of $350, amid broader sector pressures. Key influences include upcoming Q1 results with expected $6.29 billion revenue and $2.98 EPS, plus an acquisition of Amplitude Vascular Systems. A cyberattack highlighted resilience needs, but strong quarterly revenue growth of 11.4% supports positioning in high-demand orthopaedics.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top 25 AI trading bots from a library of 351, selected based on current market suitability across stocks. These bots employ diverse strategies like technical and fundamental analysis, operating on timeframes from 5 minutes to 60 minutes, and handling low to high volatility. Categorized into Signal Agents, Virtual Agents, and Brokerage Agents, they offer win rates, profit factors, and returns tailored to thousands of tickers. This dynamic selection helps traders identify high-performing options amid varying conditions, with AI-driven trends spotlighting adaptable performers. Explore the page to align bots with your trading style and market outlook.
Head-to-Head Comparison
LH and SYK both anchor healthcare but diverge in models: LH leverages recurring lab testing volumes, while SYK drives growth via innovative devices and M&A (mergers and acquisitions). Growth catalysts include LH's diagnostics expansion versus SYK's orthopaedics surge. Recent momentum favors LH slightly with monthly gains, contrasting SYK's pullback. Risk profiles align with betas of 0.99 and 0.93, though SYK faces device regulatory hurdles and cyber vulnerabilities. Sector exposure ties to healthcare tailwinds, but LH offers value at lower P/E and PEG (price/earnings-to-growth) ratios, trading sentiment buoyed by upgrades.
Tickeron AI Verdict
Tickeron’s AI currently leans toward LH with higher probability due to its compelling forward P/E of 14.79, recent FDA catalyst, and steadier short-term trend consistency below moving averages. While SYK boasts superior scale and revenue acceleration, elevated valuations and recent downside momentum temper enthusiasm ahead of earnings. This positioning suggests LH for relative value plays in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LH is a Buy and SYK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LH’s FA Score shows that 1 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- LH’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LH’s TA Score shows that 4 TA indicator(s) are bullish while SYK’s TA Score has 3 bullish TA indicator(s).
- LH’s TA Score: 4 bullish, 5 bearish.
- SYK’s TA Score: 3 bullish, 4 bearish.
Price Growth
LH (@Medical Specialties) experienced а -4.00% price change this week, while SYK (@Medical/Nursing Services) price change was -1.06% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.70%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was -3.13%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.45%. For the same industry, the average monthly price growth was -3.28%, and the average quarterly price growth was -15.87%.
Reported Earning Dates
LH is expected to report earnings on Jul 30, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical Specialties (+0.70% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+0.45% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| LH | SYK | LH / SYK | |
| Capitalization | 20.9B | 117B | 18% |
| EBITDA | 2.06B | 6.44B | 32% |
| Gain YTD | 1.949 | -13.075 | -15% |
| P/E Ratio | 22.54 | 35.27 | 64% |
| Revenue | 14.1B | 25.3B | 56% |
| Total Cash | 981M | 2.97B | 33% |
| Total Debt | 7.24B | 14.7B | 49% |
LH | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 55 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 1 Undervalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 75 | 69 | |
SMR RATING 1..100 | 68 | 57 | |
PRICE GROWTH RATING 1..100 | 56 | 62 | |
P/E GROWTH RATING 1..100 | 76 | 80 | |
SEASONALITY SCORE 1..100 | 75 | 18 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LH's Valuation (1) in the Servicestothe Health Industry industry is in the same range as SYK (9) in the Medical Specialties industry. This means that LH’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (69) in the Medical Specialties industry is in the same range as LH (75) in the Servicestothe Health Industry industry. This means that SYK’s stock grew similarly to LH’s over the last 12 months.
SYK's SMR Rating (57) in the Medical Specialties industry is in the same range as LH (68) in the Servicestothe Health Industry industry. This means that SYK’s stock grew similarly to LH’s over the last 12 months.
LH's Price Growth Rating (56) in the Servicestothe Health Industry industry is in the same range as SYK (62) in the Medical Specialties industry. This means that LH’s stock grew similarly to SYK’s over the last 12 months.
LH's P/E Growth Rating (76) in the Servicestothe Health Industry industry is in the same range as SYK (80) in the Medical Specialties industry. This means that LH’s stock grew similarly to SYK’s over the last 12 months.
| LH | SYK | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 57% | 2 days ago 55% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 65% | 2 days ago 52% |
| TrendWeek ODDS (%) | 2 days ago 52% | 2 days ago 52% |
| TrendMonth ODDS (%) | 2 days ago 50% | 2 days ago 52% |
| Advances ODDS (%) | 19 days ago 56% | 19 days ago 55% |
| Declines ODDS (%) | 2 days ago 53% | 13 days ago 53% |
| BollingerBands ODDS (%) | 2 days ago 40% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 53% | 2 days ago 47% |
Advertisement
LH and
Correlation & Price change
A.I.dvisor indicates that over the last year, LH has been closely correlated with DGX. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if LH jumps, then DGX could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.